hit counter
Aclaris Therapeutics, Inc. (ACRS) Stock News Sentiment & Price - Sentifly
ACRS - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aclaris Therapeutics, Inc. (ACRS)

USA
Biotechnology
NASDAQ
ACRS Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ACRS Latest news
GlobeNewsWire
Neutral
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
2021-11-03 07:00

WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming investor conferences:

Zacks Investment Research
Negative
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Lags Revenue Estimates
2021-11-02 09:57

Aclaris (ACRS) delivered earnings and revenue surprises of -29.63% and -9.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
2021-11-02 07:00

WAYNE, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2021 and provided a corporate update.

Zacks Investment Research
Negative
Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for
2021-10-27 16:11

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire
Neutral
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
2021-08-27 16:01

WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the “Settlement Hearing”) will be held on November 30, 2021 at 11:00 a.m. ET, before the Honorable Lewis J. Liman at the U.S. District Court for the Southern District of New York, 500 Pearl Street, New York, NY 10007 (the “Court”) in the matter of In re Aclaris Therapeutics, Inc. Derivative Litigation, Lead Case No. 1:19-cv-10641-LJL (the “Consolidated Derivative Action”).

GlobeNewsWire
Neutral
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
2021-08-26 16:01

WAYNE, Pa., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming investor conferences:

Zacks Investment Research
Positive
Should You Buy Aclaris Therapeutics (ACRS) Ahead of Earnings?
2021-08-05 12:10

Aclaris Therapeutics (ACRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlobeNewsWire
Neutral
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
2021-08-05 07:00

WAYNE, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2021 and provided a corporate update.

Zacks Investment Research
Positive
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
2021-07-30 16:43

Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

24/7 Wall Street
Neutral
Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More
2021-06-15 09:11

Tuesday's futures were fairly positive after a somewhat mixed start to the week.

Loading more news...